Alexza Amends Autoliv Agreement for Heat Packages Used in ADASUVE®

MOUNTAIN VIEW, Calif., Dec. 16, 2014 -- Alexza Pharmaceuticals, Inc. (ALXA) today announced that it amended its commercial Manufacturing and Supply Agreement ("Supply Agreement") with Autoliv ASP Inc., the North American subsidiary of Sweden-based Autoliv Inc.  Autoliv manufactures chemical heat packages, a key component of Alexza's single-dose Staccato^® system, including Alexza's commercial product ADASUVE (Staccato loxapine).

The amendment to the Supply Agreement between Alexza and Autoliv, signed on December 12, 2014, updates certain terms of prior agreements between the companies.  The Amendment states that the letter of termination received by Alexza in October 2013 is null, and that the parties are extending the agreement through 2018.  In addition, Alexza has the right to engage a second source supplier and implement a manufacturing line transfer from Autoliv to manufacture and supply the chemical heat packages to Alexza or its licensees.

Actavis and Adamas Announce FDA Approval of Namzaric™, a Fixed-Dose Combination of Memantine Extended-Release and Donepezil Hydrochloride

- Indicated for Treatment of Moderate to Severe Alzheimer's Disease -

DUBLIN and EMERYVILLE, Calif., Dec. 24, 2014 -- Actavis plc (ACT) and Adamas Pharmaceuticals Inc. (ADMS) today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Namzaric, a fixed-dose combination (FDC) of memantine hydrochloride extended-release, a NMDA receptor antagonist, and donepezil hydrochloride, an acetylcholinesterase inhibitor. Namzaric was approved for the treatment of moderate to severe dementia of the Alzheimer's type in patients stabilized on memantine hydrochloride and donepezil hydrochloride.

Vanda to regain US and Canadian rights to Fanapt®

- Vanda and Novartis Agree to Settle Arbitration
- Novartis to purchase $25 million of Vanda common stock
- Vanda to acquire rights to a Phase II clinical compound from Novartis

WASHINGTON, Dec. 22, 2014 -- Vanda Pharmaceuticals Inc. (Vanda) (VNDA) today announced that it has reached a settlement agreement with Novartis AG (Novartis) related to the ongoing Fanapt^® license arbitration proceedings.  The parties have agreed to dismiss the ongoing Fanapt^® arbitration and to release each other from any related claims. As a part of the settlement agreement, Novartis will (i) transfer all US and Canadian rights in the Fanapt^® franchise to Vanda, (ii) make a $25 million equity investment in Vanda at a price per share equal to $13.82 and (iii) grant to Vanda an exclusive worldwide license to AQW051, a phase II alpha-7 nicotinic acetylcholine receptor partial agonist.

VANC Pharmaceuticals Announces Drug Establishment License Issued by Health Canada

VANCOUVER, BRITISH COLUMBIA--(Dec 10, 2014) - VANC Pharmaceuticals Inc. (TSX VENTURE:NPH)(NUVPF) ("VANC" or the "Company"), a pharmaceutical company focused on the Canadian generic drug and over-the-counter ("OTC") markets, is pleased to announce that the Company has been issued a Drug Establishment License ("DEL") (license number 102220-A) by Health Canada. The license allows the Company to import pharmaceutical products and distribute them within Canada. The import activity covered by the license includes manufacturing pharmaceuticals at the Company's Good Manufacturing Practices ("GMP") compliant foreign site.